Accuray Incorporated (ARAY) reported quarterly earnings results on Tuesday, Apr-26-2016. The company said it had a profit of $0.01 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.08. Analysts had a consensus of $-0.07. The company posted revenue of $105.30 million in the period, compared to analysts expectations of $102.79 million. The company’s revenue was up 8.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.04 EPS.
Many Wall Street Analysts have commented on Accuray Incorporated. Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Sector Perform” and Lowered the Price Target to $ 7.50 from a previous price target of $8 .
Accuray Incorporated opened for trading at $6.13 and hit $6.235 on the upside on Friday, eventually ending the session at $6.13, with a gain of 0.41% or 0.025 points. The heightened volatility saw the trading volume jump to 3,75,120 shares. Company has a market cap of $496 M.
In a different news, on Nov 9, 2015, Joshua Levine (CEO) purchased 50,000 shares at $7.12 per share price. According to the SEC, on Sep 1, 2015, Alaleh Nouri (SVP, General Counsel &) sold 957 shares at $6.80 per share price.
Accuray Incorporated is a radiation oncology company. The Company develops manufactures sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies the CyberKnife and TomoTherapy Systems are designed to deliver treatments including radiosurgery stereotactic body radiation therapy intensity modulated radiation therapy image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH TomoHD and TomoHDA.